 Edwin deZoeten
Concepts (331)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 15 | 2023 | 364 | 3.680 |
Why?
| | T-Lymphocytes, Regulatory | 14 | 2023 | 409 | 3.130 |
Why?
| | Colitis | 12 | 2021 | 280 | 2.850 |
Why?
| | Crohn Disease | 8 | 2023 | 260 | 1.520 |
Why?
| | HSP90 Heat-Shock Proteins | 3 | 2014 | 46 | 1.110 |
Why?
| | Forkhead Transcription Factors | 9 | 2023 | 207 | 1.070 |
Why?
| | Ileitis | 3 | 2017 | 33 | 1.010 |
Why?
| | Inflammation | 9 | 2023 | 2878 | 0.950 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2018 | 1140 | 0.810 |
Why?
| | Immunity, Mucosal | 2 | 2023 | 98 | 0.780 |
Why?
| | Immune System Diseases | 1 | 2023 | 37 | 0.760 |
Why?
| | Gastroenterologists | 1 | 2023 | 21 | 0.760 |
Why?
| | Diarrhea | 2 | 2017 | 193 | 0.740 |
Why?
| | Adenosine Triphosphatases | 2 | 2014 | 159 | 0.740 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 28 | 0.740 |
Why?
| | Colitis, Ulcerative | 1 | 2023 | 148 | 0.670 |
Why?
| | Eosinophilia | 4 | 2019 | 223 | 0.670 |
Why?
| | Clostridium Infections | 2 | 2022 | 74 | 0.660 |
Why?
| | Colon | 4 | 2018 | 309 | 0.590 |
Why?
| | Fecal Microbiota Transplantation | 2 | 2022 | 27 | 0.570 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2018 | 33 | 0.570 |
Why?
| | Systems Biology | 1 | 2019 | 69 | 0.560 |
Why?
| | Enteral Nutrition | 1 | 2020 | 217 | 0.550 |
Why?
| | Colonic Diseases | 1 | 2018 | 37 | 0.540 |
Why?
| | Lactoferrin | 1 | 2017 | 36 | 0.520 |
Why?
| | DNA, Neoplasm | 4 | 2002 | 158 | 0.510 |
Why?
| | Histone Deacetylases | 5 | 2012 | 207 | 0.460 |
Why?
| | Cytoplasm | 3 | 2013 | 254 | 0.450 |
Why?
| | Precision Medicine | 1 | 2019 | 459 | 0.430 |
Why?
| | Intestinal Mucosa | 7 | 2018 | 675 | 0.420 |
Why?
| | Mice | 26 | 2023 | 18329 | 0.420 |
Why?
| | Novobiocin | 1 | 2014 | 4 | 0.420 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2022 | 1217 | 0.420 |
Why?
| | Mice, Inbred C57BL | 19 | 2018 | 5983 | 0.410 |
Why?
| | Melanoma, Experimental | 5 | 2002 | 109 | 0.410 |
Why?
| | Anus Diseases | 1 | 2013 | 8 | 0.400 |
Why?
| | Mice, Knockout | 10 | 2023 | 3124 | 0.390 |
Why?
| | Phenotype | 3 | 2019 | 3155 | 0.380 |
Why?
| | Cell Nucleus | 2 | 2014 | 588 | 0.380 |
Why?
| | Fistula | 1 | 2013 | 49 | 0.380 |
Why?
| | Abscess | 1 | 2013 | 77 | 0.380 |
Why?
| | Enzyme Inhibitors | 2 | 2014 | 820 | 0.380 |
Why?
| | Anal Canal | 1 | 2013 | 102 | 0.380 |
Why?
| | Infliximab | 4 | 2023 | 111 | 0.330 |
Why?
| | Adoptive Transfer | 3 | 2014 | 200 | 0.310 |
Why?
| | Cancer Vaccines | 4 | 2001 | 161 | 0.310 |
Why?
| | Animals | 28 | 2023 | 38030 | 0.300 |
Why?
| | Fibroblasts | 6 | 2002 | 1025 | 0.300 |
Why?
| | Heat Shock Transcription Factors | 2 | 2023 | 21 | 0.300 |
Why?
| | Dextran Sulfate | 3 | 2014 | 93 | 0.290 |
Why?
| | Interleukin-2 | 6 | 2019 | 440 | 0.290 |
Why?
| | Proprotein Convertases | 1 | 2008 | 16 | 0.290 |
Why?
| | Sucrase-Isomaltase Complex | 1 | 2008 | 1 | 0.280 |
Why?
| | Carbohydrate Metabolism, Inborn Errors | 1 | 2008 | 3 | 0.280 |
Why?
| | Biological Therapy | 1 | 2008 | 28 | 0.280 |
Why?
| | Lymphocyte Activation | 3 | 2014 | 1132 | 0.270 |
Why?
| | Biomarkers | 1 | 2019 | 4295 | 0.260 |
Why?
| | Histone Deacetylase Inhibitors | 4 | 2011 | 218 | 0.260 |
Why?
| | Interleukin-10 | 4 | 2018 | 309 | 0.250 |
Why?
| | Child | 10 | 2023 | 22707 | 0.250 |
Why?
| | Research Design | 1 | 2013 | 1137 | 0.240 |
Why?
| | Biomedical Research | 1 | 2013 | 717 | 0.240 |
Why?
| | Repressor Proteins | 1 | 2009 | 429 | 0.240 |
Why?
| | Humans | 34 | 2023 | 145475 | 0.240 |
Why?
| | Transfection | 5 | 2002 | 926 | 0.230 |
Why?
| | CTLA-4 Antigen | 2 | 2021 | 105 | 0.230 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1480 | 0.220 |
Why?
| | Remission Induction | 2 | 2020 | 307 | 0.220 |
Why?
| | Flow Cytometry | 5 | 2017 | 1162 | 0.220 |
Why?
| | Transcription Factors | 1 | 2013 | 1734 | 0.210 |
Why?
| | Mice, Transgenic | 4 | 2023 | 2188 | 0.210 |
Why?
| | H-2 Antigens | 3 | 2001 | 111 | 0.210 |
Why?
| | Immunotherapy, Adoptive | 1 | 2008 | 342 | 0.210 |
Why?
| | Autoimmune Diseases | 1 | 2008 | 468 | 0.200 |
Why?
| | Cell Proliferation | 6 | 2019 | 2507 | 0.200 |
Why?
| | Genetic Therapy | 3 | 2002 | 316 | 0.190 |
Why?
| | Adalimumab | 1 | 2023 | 55 | 0.190 |
Why?
| | Heat-Shock Response | 1 | 2023 | 77 | 0.190 |
Why?
| | Cytokines | 5 | 2018 | 2067 | 0.190 |
Why?
| | Ileum | 3 | 2023 | 112 | 0.180 |
Why?
| | Abdominal Abscess | 1 | 2022 | 26 | 0.180 |
Why?
| | Age of Onset | 1 | 2023 | 555 | 0.180 |
Why?
| | Vaccines, DNA | 2 | 1999 | 32 | 0.170 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2002 | 202 | 0.170 |
Why?
| | Intestines | 2 | 2023 | 354 | 0.170 |
Why?
| | Blotting, Western | 4 | 2015 | 1179 | 0.170 |
Why?
| | Haploinsufficiency | 1 | 2021 | 54 | 0.170 |
Why?
| | Retrospective Studies | 7 | 2022 | 17291 | 0.160 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1581 | 0.160 |
Why?
| | Pediatrics | 1 | 2008 | 1121 | 0.160 |
Why?
| | Neoplasms, Experimental | 1 | 2001 | 167 | 0.150 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 279 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1508 | 0.150 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 23 | 0.150 |
Why?
| | Celiac Disease | 1 | 2022 | 311 | 0.140 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1999 | 62 | 0.140 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2017 | 337 | 0.140 |
Why?
| | Integrins | 1 | 2019 | 90 | 0.140 |
Why?
| | Infant | 4 | 2020 | 10077 | 0.140 |
Why?
| | Feces | 2 | 2022 | 495 | 0.140 |
Why?
| | Recurrence | 2 | 2022 | 1138 | 0.140 |
Why?
| | Colonoscopy | 2 | 2017 | 263 | 0.140 |
Why?
| | Immunotherapy | 2 | 2002 | 666 | 0.140 |
Why?
| | Fibrosis | 2 | 2023 | 559 | 0.130 |
Why?
| | Th1 Cells | 1 | 2018 | 139 | 0.130 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2017 | 11 | 0.130 |
Why?
| | Disease Progression | 2 | 2019 | 2864 | 0.130 |
Why?
| | Immunoglobulin A | 2 | 2022 | 214 | 0.130 |
Why?
| | Parents | 2 | 2020 | 1403 | 0.130 |
Why?
| | Th17 Cells | 1 | 2018 | 101 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2018 | 4148 | 0.130 |
Why?
| | Attitude to Health | 1 | 2020 | 430 | 0.130 |
Why?
| | Stomach | 1 | 2017 | 111 | 0.130 |
Why?
| | Gene Deletion | 1 | 2018 | 391 | 0.130 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 81 | 0.130 |
Why?
| | Jurkat Cells | 2 | 2014 | 115 | 0.130 |
Why?
| | Killer Cells, Natural | 2 | 2019 | 480 | 0.120 |
Why?
| | Antibodies, Monoclonal | 3 | 2013 | 1505 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 699 | 0.120 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2597 | 0.120 |
Why?
| | Chronic Disease | 4 | 2022 | 1808 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 484 | 0.120 |
Why?
| | Gastrostomy | 1 | 2017 | 130 | 0.120 |
Why?
| | Mice, Inbred C3H | 5 | 2007 | 254 | 0.110 |
Why?
| | Disease Models, Animal | 5 | 2018 | 4560 | 0.110 |
Why?
| | Interleukin-33 | 1 | 2015 | 45 | 0.110 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2883 | 0.110 |
Why?
| | Signal Transduction | 3 | 2019 | 5216 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2378 | 0.110 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2015 | 47 | 0.110 |
Why?
| | Receptor, Adenosine A2B | 1 | 2015 | 65 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2018 | 249 | 0.110 |
Why?
| | Ikaros Transcription Factor | 1 | 2014 | 23 | 0.100 |
Why?
| | Marijuana Use | 1 | 2018 | 222 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1368 | 0.100 |
Why?
| | NFATC Transcription Factors | 1 | 2014 | 94 | 0.100 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2013 | 3 | 0.100 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.100 |
Why?
| | Pruritus Ani | 1 | 2013 | 2 | 0.100 |
Why?
| | Suppuration | 1 | 2013 | 9 | 0.100 |
Why?
| | Fissure in Ano | 1 | 2013 | 4 | 0.100 |
Why?
| | Genomics | 1 | 2019 | 825 | 0.100 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 86 | 0.100 |
Why?
| | Enterocolitis | 1 | 2013 | 18 | 0.100 |
Why?
| | Infant, Newborn | 2 | 2023 | 6447 | 0.100 |
Why?
| | Motivation | 1 | 2018 | 600 | 0.100 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 94 | 0.100 |
Why?
| | Plasma Cells | 1 | 2013 | 79 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1996 | 0.090 |
Why?
| | Leukocyte Common Antigens | 1 | 2013 | 87 | 0.090 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2012 | 9 | 0.090 |
Why?
| | Lactams, Macrocyclic | 1 | 2013 | 51 | 0.090 |
Why?
| | Benzoquinones | 1 | 2013 | 46 | 0.090 |
Why?
| | Adolescent | 5 | 2018 | 22530 | 0.090 |
Why?
| | Fecal Incontinence | 1 | 2013 | 90 | 0.090 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 838 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2014 | 762 | 0.090 |
Why?
| | alpha 1-Antitrypsin | 1 | 2013 | 104 | 0.090 |
Why?
| | MicroRNAs | 1 | 2018 | 686 | 0.090 |
Why?
| | Glutathione Transferase | 1 | 2012 | 92 | 0.090 |
Why?
| | Female | 12 | 2018 | 78845 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 992 | 0.090 |
Why?
| | Wet Macular Degeneration | 1 | 2012 | 58 | 0.090 |
Why?
| | Histone Deacetylase 6 | 1 | 2011 | 17 | 0.080 |
Why?
| | Consensus | 1 | 2013 | 477 | 0.080 |
Why?
| | Protein Transport | 1 | 2013 | 442 | 0.080 |
Why?
| | Consent Forms | 1 | 2011 | 12 | 0.080 |
Why?
| | Gene Targeting | 1 | 2011 | 81 | 0.080 |
Why?
| | Microarray Analysis | 1 | 2011 | 116 | 0.080 |
Why?
| | Transplantation Tolerance | 1 | 2011 | 39 | 0.080 |
Why?
| | Immunoprecipitation | 1 | 2011 | 148 | 0.080 |
Why?
| | Computers | 1 | 2011 | 66 | 0.080 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1261 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 680 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 977 | 0.080 |
Why?
| | Anilides | 1 | 2011 | 84 | 0.080 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 296 | 0.080 |
Why?
| | Autoimmunity | 2 | 2019 | 933 | 0.080 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 886 | 0.080 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 679 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2022 | 11772 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 75 | 0.070 |
Why?
| | Antigens, Neoplasm | 3 | 2001 | 271 | 0.070 |
Why?
| | Male | 10 | 2018 | 72843 | 0.070 |
Why?
| | Informed Consent | 1 | 2011 | 198 | 0.070 |
Why?
| | Epitopes | 2 | 2002 | 473 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 82 | 0.070 |
Why?
| | Retroviridae | 1 | 2008 | 100 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2015 | 1131 | 0.070 |
Why?
| | Growth | 1 | 2008 | 49 | 0.070 |
Why?
| | Oxazolone | 1 | 2008 | 5 | 0.070 |
Why?
| | Picrates | 1 | 2008 | 5 | 0.070 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 2008 | 10 | 0.070 |
Why?
| | Bystander Effect | 1 | 2008 | 19 | 0.070 |
Why?
| | Homeostasis | 1 | 2012 | 642 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2008 | 387 | 0.070 |
Why?
| | Endoscopy | 1 | 2011 | 317 | 0.070 |
Why?
| | RNA, Messenger | 3 | 2013 | 2803 | 0.070 |
Why?
| | Hemorrhage | 1 | 2013 | 822 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1041 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 4075 | 0.070 |
Why?
| | Pain | 1 | 2013 | 789 | 0.070 |
Why?
| | Transplantation Immunology | 1 | 2007 | 29 | 0.070 |
Why?
| | Immunization | 2 | 2001 | 375 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2015 | 638 | 0.060 |
Why?
| | Graft Rejection | 1 | 2011 | 521 | 0.060 |
Why?
| | Child, Preschool | 3 | 2017 | 11853 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2009 | 260 | 0.060 |
Why?
| | Indoles | 1 | 2011 | 507 | 0.060 |
Why?
| | DNA Methylation | 1 | 2012 | 674 | 0.060 |
Why?
| | Cohort Studies | 1 | 2017 | 6013 | 0.060 |
Why?
| | Cell Line | 3 | 2002 | 2823 | 0.060 |
Why?
| | Cell Survival | 1 | 2009 | 1100 | 0.060 |
Why?
| | Antigens, CD | 1 | 2008 | 558 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2008 | 666 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 477 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 2129 | 0.050 |
Why?
| | Hypoxia | 1 | 2012 | 1199 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2008 | 523 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 740 | 0.050 |
Why?
| | Chromatin | 1 | 2008 | 553 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2008 | 673 | 0.050 |
Why?
| | Macrophages | 1 | 2012 | 1507 | 0.050 |
Why?
| | Transplantation, Homologous | 2 | 2022 | 418 | 0.050 |
Why?
| | Cell Movement | 1 | 2008 | 959 | 0.050 |
Why?
| | Aged | 1 | 2023 | 26153 | 0.050 |
Why?
| | Cellulitis | 1 | 2022 | 54 | 0.040 |
Why?
| | Duodenum | 1 | 2022 | 77 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1747 | 0.040 |
Why?
| | Transglutaminases | 1 | 2022 | 159 | 0.040 |
Why?
| | Necrosis | 1 | 2022 | 244 | 0.040 |
Why?
| | Acute Disease | 2 | 2015 | 1036 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2018 | 1246 | 0.040 |
Why?
| | Age Factors | 1 | 2008 | 3342 | 0.040 |
Why?
| | Mice, Inbred DBA | 1 | 2001 | 182 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1998 | 177 | 0.040 |
Why?
| | Cell Transplantation | 1 | 1999 | 39 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2007 | 2046 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 52 | 0.040 |
Why?
| | Survival Analysis | 2 | 1999 | 1374 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2019 | 95 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 199 | 0.040 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2018 | 24 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 196 | 0.030 |
Why?
| | Gastritis | 1 | 2019 | 116 | 0.030 |
Why?
| | Enteritis | 1 | 2019 | 104 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2019 | 319 | 0.030 |
Why?
| | Cell Division | 1 | 1999 | 756 | 0.030 |
Why?
| | Vaccines, Synthetic | 1 | 1998 | 137 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 206 | 0.030 |
Why?
| | Time Factors | 1 | 2008 | 7123 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 65 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1998 | 174 | 0.030 |
Why?
| | Quality of Life | 1 | 2008 | 3204 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 1999 | 919 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 977 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2018 | 471 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 641 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2015 | 119 | 0.030 |
Why?
| | Peroxidase | 1 | 2015 | 168 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 881 | 0.030 |
Why?
| | Fibronectins | 1 | 2015 | 136 | 0.030 |
Why?
| | Glioma | 1 | 1999 | 429 | 0.030 |
Why?
| | NF-kappa B | 1 | 2018 | 666 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1509 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2015 | 146 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2015 | 249 | 0.030 |
Why?
| | Chemokines | 1 | 2015 | 217 | 0.030 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 181 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 365 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1598 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 132 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2013 | 21 | 0.020 |
Why?
| | B-Cell Maturation Antigen | 1 | 2013 | 17 | 0.020 |
Why?
| | Self Report | 1 | 2018 | 870 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 88 | 0.020 |
Why?
| | Cytidine Deaminase | 1 | 2013 | 59 | 0.020 |
Why?
| | Eosinophils | 1 | 2015 | 316 | 0.020 |
Why?
| | Collagen | 1 | 2015 | 457 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 319 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 506 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2012 | 45 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2013 | 265 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6066 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 1999 | 925 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 163 | 0.020 |
Why?
| | Retinal Pigment Epithelium | 1 | 2012 | 79 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2012 | 247 | 0.020 |
Why?
| | Acetylation | 1 | 2012 | 259 | 0.020 |
Why?
| | Choroid | 1 | 2012 | 80 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2460 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2923 | 0.020 |
Why?
| | Exons | 1 | 2012 | 363 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 475 | 0.020 |
Why?
| | Prospective Studies | 2 | 2015 | 8057 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 749 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 1999 | 1329 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2012 | 385 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3623 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 474 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 892 | 0.020 |
Why?
| | Infant, Premature | 1 | 2013 | 619 | 0.020 |
Why?
| | Interleukin-1 | 1 | 2012 | 961 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 175 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1476 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1716 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2013 | 870 | 0.020 |
Why?
| | Mice, Congenic | 1 | 2007 | 23 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4554 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2001 | 2664 | 0.020 |
Why?
| | Diet | 1 | 2015 | 1277 | 0.020 |
Why?
| | Histones | 1 | 2012 | 666 | 0.020 |
Why?
| | Mice, SCID | 1 | 2007 | 369 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 312 | 0.020 |
Why?
| | Organ Transplantation | 1 | 2009 | 251 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5905 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 381 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2012 | 1356 | 0.010 |
Why?
| | Communication | 1 | 2011 | 975 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 14219 | 0.010 |
Why?
| | Killer Cells, Lymphokine-Activated | 1 | 1999 | 12 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1999 | 246 | 0.010 |
Why?
| | Adult | 1 | 2022 | 40777 | 0.010 |
Why?
| | Ouabain | 1 | 1998 | 18 | 0.010 |
Why?
| | Melanoma-Specific Antigens | 1 | 1998 | 2 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1998 | 49 | 0.010 |
Why?
| | Middle Aged | 1 | 2017 | 36215 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 1998 | 384 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 1998 | 441 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 1998 | 881 | 0.010 |
Why?
| | Vaccination | 1 | 1998 | 1426 | 0.000 |
Why?
|
|
deZoeten's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|